FDA notifications.  FDA gives tentative approval for stavudine, lamivudine & nevirapine tablet.
D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004338:Drug Combinations; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D019829:Nevirapine / Q000008:administration & dosage / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D018119:Stavudine / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D004338:Drug Combinations; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D019829:Nevirapine; D018119:Stavudine